A Study to Investigate the PK and Safety of CKD-393

NCT04768673 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Type II Diabetes

Interventions

DRUG: CKD-393 formulation I
DRUG: CKD-393 formulation II
DRUG: D501, D759, H053

Sponsor

Chong Kun Dang Pharmaceutical